Eric Halioua

Company: PDC*line Pharma

Job title: President & Chief Executive Officer

Seminars:

Reporting Clinical Data from a First-in-Class Plasmacytoid Dendritic Cell Line Vaccine in Patients with Metastatic NSCLC 10:00 am

• Understanding the characteristics and applications of the PDC*vac technology as a novel allogeneic cancer vaccine • Reviewing early safety, tolerability, and immunogenicity findings from this phase one trial • Discussing initial signs of clinical activity associated with the vaccine in NSCLC patientsRead more

day: Day Two